A Phase 1 interventional study of Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg and Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg in Healthy Volunteers and Fasting Conditions, sponsored by LG Chem. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by LG Chem · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Bioequivalence study for the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg under fasting conditions in healthy volunteers
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
test drug \> reference drug
Drug: Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg
reference drug \> test drug
Drug: Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg
All participants will take 1 tablet of either test drug or 2 tablets of reference drug with fasting conditions.
Drug page: Gemigliptin
All participants will take 1 tablet of either test drug or 2 tablest of reference drug with fasting conditions.
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
Area under the plasma concentration versus time curve (AUClast) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
Peak Plasma Concentration (Cmax) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin.
Time to Maximum Concentration(Tmax) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
Lag Time(Tlag) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
Area Under the Curve to Infinity(AUCinf) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
Half-life(t1/2) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
Apparent Clearance(CL/F) of Gemigliptin, Dapagliflozin, and Metformin
Time frame: Up to 72 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Feb 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemigliptin